Analysis
Thermo Fisher Scientific (TMO) experienced a significant financial impact from the tariffs introduced in April 2025, primarily affecting its U.S.-China trade and broader macroeconomic environment. In its Transcript 1Q-2025, management updated its full-year 2025 guidance to incorporate a $900M revenue headwind, of which $400M was directly attributed to reciprocal U.S.-China tariffs. These tariffs were expected to significantly reduce trade volumes for U.S.-made products sold in China and increase the cost of China-sourced components. The company also identified a $500M revenue headwind stemming from related U.S. policy changes, which caused hesitancy among academic and government customers regarding funding and led to cancellations of government-funded clinical trials.
The net impact of these tariffs on profitability was substantial, with the company estimating a $375M headwind to 2025 adjusted operating income specifically from U.S.-China tariffs. This figure reflects the combined effect of lost sales volumes and higher input costs, partially offset by aggressive mitigation efforts. Non-China related tariffs were expected to have no net adjusted EPS impact for 2025, as management believed supply chain adjustments and pricing actions would fully offset those costs within the year. The total impact of tariffs and related foreign exchange volatility was estimated to reduce adjusted operating income margins by approximately 120bps in the initial April update, though this was later refined to a headwind of over 100bps for the full year 2025 as reported in the Transcript FY-2025.
To mitigate the impact of tariffs, Thermo Fisher leveraged its PPI Business System to manage its cost base and supply chain. Mitigation strategies included moving production of certain products to different geographic sites and initiating a $2B investment in U.S. manufacturing and R&D over a four-year period to capitalize on reshoring trends. The company also implemented appropriate pricing actions to pass through some of the inflationary pressure. While these mitigation efforts took time to execute, management expected the full benefits to be realized by 2026, leading to a rapid reduction in the net financial headwind from these trade policies.
As of early 2026, Thermo Fisher's guidance for the year is based on the tariffs currently in place. The Annual Report FY-2025 confirms that while the Analytical Instruments segment was particularly pressured by tariffs and related FX—resulting in a 320bps decline in segment income margin—the company as a whole has navigated the environment through productivity improvements and share gains. Management remains focused on retiring remaining risks as the benefits of their global manufacturing footprint and supply chain agility continue to materialize.
Data
($M)
| Financial Impact of 2025 Macro Changes | 2025 Estimated Headwind |
|---|---|
| China Tariff Revenue Impact | $400 |
| China Tariff Operating Income Impact | 375 |
| U.S. Policy Focus Revenue Impact | 500 |
| U.S. Policy Focus Operating Income Impact | 150 |
| Total Adjusted EPS Impact (per share) | $1.00 |
Source: Transcript 1Q-2025, Marvin Labs
Financial Impact
- Revenue Impact (Historic): $400M
- Cost Impact (Historic): $375M
Sources
The tariff rates here are so substantial that they're likely to significantly reduce the volume of trade between the two countries. We expect this will impact the sales of our products in China that are produced by our facilities in the U.S.
The tariff related changes to the guide reduce our adjusted operating income margin by 120 basis points. This is driven by FX and also the tariff costs, partially offset by incremental pricing actions.
We expect this impact will reduce very rapidly next year when the full benefits of our mitigation actions are realized. Once they are complete, we expect them to fully mitigate the impact of these tariffs.